Microbiotica raises £36m in Series C financing

|
FOR RELEASE ON |
16 October 2026
|
Portfolio company Microbiotica raises £36m in Series C financing to advance pipeline into Phase 2 clinical development
IP Group plc ("IP Group" or the "Group") (LSE: IPO), which invests in breakthrough science and technology companies with the potential to create a better future for all, is pleased to note that portfolio company Microbiotica Ltd ("Microbiotica" or "the Company") has closed a £36m Series C financing.
Microbiotica, a clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines, noted the capital will support the advancement of MB310 into Phase 2 clinical development in ulcerative colitis. This follows positive results from the COMPOSER-1 Phase 1b study, which met its primary and secondary endpoints and demonstrated statistically significant improvements in clinical remission versus placebo.
IP Group invested £4m in the financing round, which was led by British Business Bank with participation from other existing investors Tencent, Cambridge Innovation Capital, Flerie Invest and Seventure Partners. Following second completion, IP Group will have an undiluted beneficial holding of 16.4% in Microbiotica, valued at £24.1m.
Greg Smith, Chief Executive of IP Group, said: "Microbiotica has made exciting progress in translating world-class microbiome science into potential new medicines for patients. The positive results from MB310 provide a strong foundation for its next stage of development, and we are pleased to increase our investment alongside a high-quality syndicate of investors. We look forward to supporting the team as it takes this highly innovative approach forward."
For more information, please contact:
|
IP Group plc |
www.ipgroupplc.com |
|
Liz Vaughan-Adams, Communications |
+44 (0) 20 7444 0062/+44 (0) 7967 312125 |
|
Portland |
|
|
Lewis Bendall-Craft |
+44 (0) 7931 973950 |
Notes for editors
About IP Group
IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world's most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, we back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
For more information, please visit our website at www.ipgroupplc.com.
About Microbiotica
Microbiotica is a private, clinical-stage, biopharma company developing oral precision microbiome medicines called live biotherapeutic products (LBPs). Its lead programme, MB310, is being developed for ulcerative colitis and has demonstrated promising clinical activity and a favourable safety profile in a Phase 1b study. Microbiotica is also advancing a pipeline of immuno-oncology programmes, including MB097 in combination with KEYTRUDA® (pembrolizumab) for advanced melanoma, which has met its trial endpoints and is progressing through a Phase 1b extension phase.
Microbiotica's proprietary, genomics-driven microbiome profiling platform enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. This clinical-data led approach informs the selection of bacterial strains for therapeutic development with the potential to improve the likelihood of clinical success.
Spun out of the Wellcome Sanger Institute in 2016, the Company is based in purpose-built facilities at the Chesterford Research Park near Cambridge, UK. Microbiotica is backed by British Business Bank, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent. The Company has also received financial support from the US-based Crohn's and Colitis Foundation.
For more information, please visit www.microbiotica.com.
ENDS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE